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The Ontario Neurodegenerative Research Initiative (ONDRI) is a 3 years multi-site
prospective cohort study that has acquired comprehensive multiple assessment
platform data, including 3T structural MRI, from neurodegenerative patients with
Alzheimer’s disease, mild cognitive impairment, Parkinson’s disease, amyotrophic lateral
sclerosis, frontotemporal dementia, and cerebrovascular disease. This heterogeneous
cross-section of patients with complex neurodegenerative and neurovascular
pathologies pose significant challenges for standard neuroimaging tools. To effectively
quantify regional measures of normal and pathological brain tissue volumes, the ONDRI
neuroimaging platform implemented a semi-automated MRI processing pipeline that
was able to address many of the challenges resulting from this heterogeneity. The
purpose of this paper is to serve as a reference and conceptual overview of the
comprehensive neuroimaging pipeline used to generate regional brain tissue volumes
and neurovascular marker data that will be made publicly available online.
Keywords: MRI, Alzheimer, Parkinson, amyotrophic lateral sclerosis, frontotemporal dementia, cerebrovascular
disease, stroke, cerebral small vessel disease

INTRODUCTION
The Ontario Neurodegenerative Research Initiative (ONDRI) is a multi-site prospective cohort
study following patients with neurodegenerative diseases including Alzheimer’s disease (AD),
mild cognitive impairment (MCI), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS),
frontotemporal dementia (FTD), and cerebrovascular disease (CVD). Over the course of 3 years,
multiple assessment platforms acquired comprehensive data from the 520 patients including:
neuroimaging (1–3), clinical and demographic assessments (4), neuropsychology (5), genetic
variations (6, 7), eye tracking and pupillometry, retinal layer analyses using spectral-domain optical
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coherence tomography (8), gait and balance performance (9), and
neuropathology. The multi-modal data collected from ONDRI
will be used to explore earlier detection, guide development of
novel therapy, and improve patient care. ONDRI’s mission is
to bring new diagnostic biomarkers and prognostic tools into
clinical practice in order track disease progression and potential
response to future symptomatic and disease-modifying therapies
targeting dementia/cognitive impairment.
This paper describes the methods implemented to extract
normal and pathological brain tissue volumetric information
from the structural Magnetic Resonance Imaging (MRI)
provided by the ONDRI neuroimaging platform. It includes
a comprehensive methodological overview of the structural
neuroimaging pipeline’s previously published and validated
components, with numerous figures to provide a visual
description of how the measures were obtained from the MRI,
some recommendations for reporting and data analysis, and
a brief section providing some basic descriptive statistics to
illustrate the whole brain volumetrics that can be obtained from
the ONDRI patient cohorts.
Structural MRI processing for volumetrics was performed
by the neuroimaging group in the L.C. Campbell Cognitive
Neurology Research Unit, within the Hurvitz Brain Sciences
Research Program, at the Sunnybrook Research Institute, in
Toronto, Canada. The image processing pipeline (Figure 1)
has been optimized for an aging population, with a particular
emphasis on accounting for chronic stroke and post stroke

cortical and subcortical lesions, numerous imaging markers of
cerebral small vessel disease, as well as, the focal and global brain
atrophy observed in neurodegenerative patient populations such
as AD and FTD.
The main goal of this paper is to highlight the overall
features of the neuroimaging pipeline that would be of interest
to a neurologist, clinician, or non-imaging researcher seeking
to utilize the ONDRI data that will be made publicly available
through an application process on October, 2020. For more
information on the ONDRI project, please visit: http://ondri.ca/.

METHODS
Study Participants
Ethics approval was obtained from all participating institutions.
Participants were recruited at 14 health centers across six
cities in Ontario, Canada: Hamilton General Hospital and
McMaster Medical Centre in Hamilton; Hotel Dieu Hospital
and Providence Care Hospital in Kingston; London Health
Science Centre and Parkwood Institute in London; Elizabeth
Bruyère Hospital and The Ottawa Hospital in Ottawa; Thunder
Bay Regional Health Sciences Centre in Thunder Bay; and
Baycrest Health Sciences (Baycrest), Centre for Addiction
and Mental Health (CAMH), St. Michael’s Hospital (SMH),
Sunnybrook Health Sciences Centre (Sunnybrook), and
Toronto Western Hospital—University Health Network (UHN)
in Toronto.

FIGURE 1 | ONDRI MRI processing pipeline overview. General workflow moves from left to right for final volumetric output resulting in a comprehensive spreadsheet
in the form of a .csv file. Hippocampal volumes are segmented using the SBHV method (10) which was fully integrated into the pipeline and are included in the final
volumetric spreadsheet. Microbleed Rating, Resting State fMRI Analysis, and Diffusion Tensor Imaging (DTI) analyses are processed separately, however, the DTI and
Cortical Thickness pipelines are dependent on some components of the primary pipeline, thus, results from these processes are provided in separate spreadsheets.
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SABRE-Lesion Explorer (SABRE-LE) (20–23). This is a
semi-automated personalized approach to imaging-based
quantification, as it can provide a comprehensive volumetric
profile at the individual patient level. While it may take longer
to process each individual relative to fully automatic methods,
this careful patient-focused approach is more robust to the large
variability in stroke and neurodegenerative patient population.
This method has been previously validated (23–25) and
implemented in other Canadian studies (26–29). The following
sections describe the SABRE-LE comprehensive pipeline method
and the volumetric data that is extracted in greater detail. Data
visualization was performed using RStudio version 1.2.1335
(RStudio, Inc., Boston, MA) and ITKSnap (30).

Full study participant details are previously described (4).
Briefly, AD/MCI patients met National Institute on Aging
Alzheimer’s Association criteria for probable or possible AD,
or MCI (11, 12); PD patients met criteria for idiopathic PD
defined by the United Kingdom’s Parkinson’s Disease Society
Brain Bank clinical diagnostic criteria (13); ALS patients met
El Escorial World Federation of Neurology diagnostic criteria
for possible, probable, or definite familial or sporadic ALS
(14); FTD patients included possible or probable behavioral
variants of frontotemporal degeneration (15), agrammatic/nonfluent and semantic variants of primary progressive aphasia
(16), and possible or probable progressive supranuclear palsy
(17); CVD patients experienced a mild to moderate ischemic
stroke event, verified on neuroimaging, 3 or more months prior
to enrollment in compliance with the National Institute of
Neurological Disorders and Stroke-Canadian Stroke Network
vascular cognitive impairment harmonization standards (18).
For illustrative purposes of the neuroimaging pipeline
outputs, baseline MRI data are included for the following ONDRI
patient cohorts: 126 AD/MCI, 140 PD, 40 ALS, 53 FTD, and
161 CVD.

Brain Regions of Interest: SABRE
The neuroimaging pipeline integrates a brain region parcellation
process called Semi-Automatic Brain Region Extraction (SABRE)
(20). This method separates the brain into 26 regions of interest
(ROIs: 13 per hemisphere) derived from anatomical landmarks
manually identified per hemisphere on each individual patient
(Figure 2 and Table 1). Each imaging analyst was required
to achieve an intraclass correlation coefficient (ICC) > 0.90
in order to work on ONDRI patient imaging analysis. The
automatic SunnyBrook Hippocampal Volumetry (SBHV) tool
(10) was subsequently integrated into the SABRE pipeline
(Figure 3), resulting in a total of 28 ROIs (left + right
hippocampus) (see following section). The SABRE brain maps
are personalized maps that are unique to each individual
patient and was developed from the Talairach grid system
(31). Relative to many brain mapping methods that implement
non-linear (i.e., “warping”) techniques to register an individual

MRI Acquisition
Neuroimaging was acquired at the following sites using each
site’s respective 3T MRI system: a General Electric (GE,
Milwaukee, WI) Discovery 750 was used at Sunnybrook,
McMaster University/Hamilton General Hospital, and CAMH;
a GE Signa HDxt at UHN; a Philips Medical Systems (Philips,
Best, Netherlands) Achieva system at Thunder Bay Regional
Health Sciences Centre; a Siemens Health Care (Siemens,
Erlangen, Germany) Prisma at Sunnybrook and London
Health Sciences Centre/Parkwood Hospital; a Siemens TrioTim
at Ottawa Hospital/Élisabeth Bruyère Hospital, Hotel Dieu
Hospital/Providence Care Hospital and Baycrest; and a Siemens
Skyra at SMH.
Harmonized with the Canadian Dementia Imaging Protocol
(19), the National Institute of Neurological Disorders
and Stroke–Canadian Stroke Network Vascular Cognitive
Impairment Harmonization Standards (18), full MRI acquisition
protocol details for each imaging site are provided on
Supplementary Table 1. In brief, the following structural
MRI sequences were obtained for each study participant: 3D
T1-weighted (T1), T2-weighted fluid attenuated inversion
recovery (FLAIR), interleaved T2-weighted and proton density
(T2/PD), and T2∗ gradient recalled echo (GRE). It should
be noted that additional imaging protocol included a 30/32
direction diffusion tensor imaging (DTI), resting state functional
MRI, and arterial spin labeling (acquired only at one site), but are
beyond the scope of this paper and will be presented elsewhere
(1). Prior to image processing for volumetric quantification, MRI
were fully evaluated by a neuroradiologist (SS) for incidental
findings and for imaging quality by a medical biophysics
scientist (RB).

FIGURE 2 | A 3-D surface volume rendering of T1-weighted MRI showing
right hemisphere SABRE regions in different colours. Left hemisphere regions
were made translucent for illustrative purposes, however, SABRE regions are
separately parcellated for each hemisphere and delineated using individualized
anatomical landmarks for both left and right sides.

Structural Image Processing Methods:
Overview
The structural neuroimaging pipeline used in ONDRI is
a component based algorithm commonly referred to as
Frontiers in Neurology | www.frontiersin.org
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TABLE 1 | SABRE-LE neuroimaging pipeline brain tissue and lesion codes (top),
and detailed SABRE brain region codes (bottom).
Imaging descripton

Code

Supratentorial total intracranial
volume

ST_TIV

Normal appearing gray matter

NAGM

Normal appearing white matter

NAWM

Sulcal cerebrospinal fluid

CSF

Ventricular cerebropsinal fluid

CSF

Periventricular white matter
hyperintensities

Pwmh

Deep white matter hyperintensities

dWMH

Periventricular lacunes

pLACN

Deep lacunes

dLACN

Enlarged perivascular spaces

PVS

Chronic stroke lesions

Stroke

SABRE brain region name

Code

Lobe

Superior frontal

SF

Frontal

Middle frontal

MF

Frontal

Inferior frontal

IF

Frontal

Medial inferior frontal

MIF

Frontal

Medial superior frontal

MSF

Frontal

Medial middle frontal

MMF

Frontal

Superior parietal

SP

Parietal

Inferior parietal

IP

Parietal

Occipital

O

Occipital

Anterior temporal

AT

Temporal

Posterior temporal

PT

Temporal

Anterior basal ganglia/thalamus

ABGT

Basal
ganglia/thalamus

Posterior basal ganglia/thalamus

PBGT

Basal
ganglia/thalamus

Hippocampus

HP

Medial temporal

FIGURE 3 | The SunnyBrook Hippocampal Volumetric (SBHV) segmentation
showing left (BLUE) and right (GREEN) hippocampi overlayed on an axial T1
MRI and extracted as 3-D surface volume renderings. Note images are in
radiological convention.

and right hippocampal sub-classifications for parenchyma,
hypointensities, and stroke volumes (when present). Currently,
there is some controversy over the pathophysiological origin
and relevance of small cavities commonly observed in the
hippocampus (35–38), which are particularly relevant in the
ONDRI CVD patients. Additionally, large cortico-subcortical
strokes can extend from the cortex into the hippocampus.
Given these vascular issues potentially affecting the overall
hippocampal volume, ONDRI provides sub-classifications for
parenchyma, hypointensities, and stroke volumes based on the
neuroimaging characteristics (i.e., intensity) using the voxel
segmentation classifications and takes a neutral stance on
the pathophysiological origin of small cavities observed in
this region.

Note that each regional code will be preceded by an “L” or “R” indicating the left or
right hemisphere.

patient’s MRI to a standardized template, such as the Montreal
Neurological Institute brain (MNI152) (32), the SABRE approach
is essentially reversed, by mapping a brain template onto the
individual patient’s MRI. This method accounts for natural
individual differences in anatomy but more importantly, it
is a method that can compensate for significant focal and
global brain atrophy that is found in stroke, dementia, and
neurodegenerative patients.

Total Intracranial Volume
The supratentorial total intracranial volume (ST-TIV) is a
measure of all brain matter that is located below the dura
mater. It is referred to as supratentorial because the SABRE-LE
method removes all tissue below the tentorium, including the
cerebellum and portions of the brain stem (20, 22). Although the
removal of infratentorial structures was necessary for technical
segmentation reasons, researchers particularly interested in
the cerebellum, and brainstem can apply additional imaging
tools [e.g., (39)] to obtain these structures from the original
acquisitions upon special request.
In addition to sex-related differences, there are also normal
variations in head size. In order to account for these differences,
most neuroimaging studies implement some form of head-size
correction. This is also particularly important when assessing
brain atrophy in cross-sectional studies, as a true measure of

Hippocampus
The hippocampus is an important part of the limbic system that
has been studied extensively in dementia, given its significant role
in memory functions (33, 34). The ONDRI pipeline incorporates
the multi-atlas based Sunnybrook Hippocampal Volumetric
(SBHV) segmentation tool (Figure 3) that was developed and
validated using the Sunnybrook Dementia Study and the
Alzheimer’s Disease Neuroimaging Initiative (ADNI1) (10).
For ONDRI, the SBHV segmentation has been fully
integrated into the SABRE-LE pipeline, and includes left

Frontiers in Neurology | www.frontiersin.org
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FIGURE 4 | Axial views of T1-weighted MRI from an ONDRI FTD patient. Red arrows point to regions with significant focal brain atrophy. The SABRE-LE processing
pipeline accounts for this focal atrophy since it includes a measure of everything below the dura mater, including sub-arachnoid and sulcal cerebrospinal fluid (CSF),
shown in purple.

removal of non-brain tissue (24). This automatic segmentation
method deals with scanner inhomogeneities by fitting localized
histograms to Gaussians to allocate voxels into gray matter (GM),
white matter (WM), and cerebrospinal fluid (CSF) tissue classes.
After manual ventricular CSF (vCSF) relabelling, there are four
brain tissue types that are segmented for volumetrics using
SABRE-LE (Table 2):

the total intracranial capacity will provide an indication of
where “there used to be brain and now there is cerebrospinal
fluid (CSF).” The presence of focal atrophy due to stroke
and neurodegenerative processes tends to result in over and
under erosion errors with many fully automated T1-based skull
stripping techniques, due to the similarity in intensity between
background and sulcal CSF. The SABRE-LE method accounts
for the presence of focal atrophy since it includes a measure
of everything below the dura mater, including sub-arachnoid
CSF, thus, providing a more accurate measure of head-size in
neurodegenerative patient populations (Figure 4).
It is important to note that there are numerous acceptable
head-size correction methods reported in the literature (40). A
simple method involves dividing each volume of interest by the
total head size to obtain a proportional volume (41). ONDRI
provides raw volumes and head size volumes (i.e., ST-TIV) for
each individual patient.

•
•
•
•

The T1-based tissue segmentation is further corrected for
misclassified volumes using a PD-T2/FLAIR-based lesion
segmentation algorithm to account for the voxels appearing
as GM or CSF on T1 (42) due to WM changes from stroke
and cerebral small vessel disease. For this reason, the GM and
WM volumes are denoted as “normal appearing” (NAGM,
NAWM) to signify that these volumes have been re-labeled as
normal appearing after having been corrected with an additional
multi-modal MRI segmentation approach (Figure 5). Additional

Brain Tissue Segmentation
A robust T1 intensity-based brain tissue segmentation, optimized
for aging and dementia, is performed after skull stripping and

Frontiers in Neurology | www.frontiersin.org

Normal appearing gray matter (NAGM)
Normal appearing white matter (NAWM)
Sulcal cerebrospinal Fluid (sCSF)
Ventricular CSF (vCSF).
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TABLE 2 | Data is shown as mean (standard deviation) unless otherwise specified. Raw values are presented for transparency purposes.
Demographics
Number of participants
Age, years
Sex, n (%) female

AD/MCI

ALS

FTD

PD

CVD

126

40

52

140

155

71.0 (8.2)

62.0 (8.7)

67.8 (7.1)

67.9 (6.3)

69.3 (7.4)

57 (45.2)

16 (40.0)

19 (36.5)

31 (22.1)

48 (31.0)

ST-TIV, cc

1235.6 (144.6)

1203.6 (162.8)

1245.8 (129.6)

1316.6 (127.0)

1224.5 (133.2)

NAWM, cc

395.4 (344.5)

425.0 (78.8)

295.1 (59.4)

446.1 (61.2)

387.4 (54.4)

NAGM, cc

533.3 (51.4)

556.2 (65.7)

252.5 (56.0)

574.7 (47.1)

535.7 (52.3)

sCSF, cc

256.3 (62.1)

195.9 (52.9)

277.0 (57.8)

252.3 (53.3)

242.6 (59.3)

vCSF, cc

45.7 (28.4)

23.8 (11.1)

43.7 (16.6)

38.2 (19.4)

41.3 (23.0)

pWMH*, mm3

2564.5 (2811.2)

1040.0 (1252.5)

2736.0 (1623.8)

2563.5 (2708.0)

4054.0 (7468.0)

dWMH*, mm3

289.5 (424.7)

208.0 (386.5)

138.5 (379.3)

259.5 (225.7)

555.0 (584.0)

LACN*, mm3

15.5 (66.0)

14.5 (12.2)

9.5 (55.5)

17.5 (70.0)

92.0 (291.0)

PVS*, mm3

45.5 (35.5)

17.5 (9.5)

32.5 (36.3)

34.0 (30.0)

44.0 (33.0)

–

90.0a

393.0 (294.0)b

531.5 (1269.0)c

4644.5 (12963.0)d

Stroke*, mm3
* Data

is shown as median (interquartile range). a Available in 1/40 participants. b Available in 6/52 participants. c Available in 4/140 participants. d Available in 88/155 participants AD/MCI,
Alzheimer’s Disease and Mild Cognitive Impairment; ALS, Amyotrophic Lateral Sclerosis; FTD, Frontotemporal Dementia; PD, Parkinson’s Disease; VCI, Vascular Cognitive Impairment;
ST-TIV, supratentorial total intracranial volume; NAWM, normal appearing white matter; NAGM, normal appearing gray matter; sCSF, sulcal cerebrospinal fluid; vCSF, ventricular
cerebrospinal fluid; pWMH, periventricular white matter hyperintensities; dWMH, deep white matter hyperintensities; LACN, lacunes; PVS, perivascular spaces.

FIGURE 5 | Due to relative intensities on different MRI sequences, WMH (red arrows) on T2 FLAIR are not hyperintense (bright) on T1-weighted images and tend to
appear as GM (gray) or CSF (blue) intensity on T1. Thus, T1-based segmentations tend to inflate the GM and CSF volumes in patients with stroke and cerebral small
vessel disease. To account for this, ONDRI’s imaging pipeline integrates an additional T2/FLAIR-based WMH segmentation to correct for this misclassification error
(42) to produce a normal appearing WM/GM (NAWM/NAGM) volumes.

brain tissue volumes for stroke lesions and cerebral small vessel
disease markers are discussed in the following sections.
The NAGM and NAWM volumes can be summed to obtain
a measure of parenchymal volume or reported individually
for head-size corrected measures to assess potential atrophy.
Additionally, a segmentation mask is generated which is
used for diffusion tensor imaging (DTI) analyses, where
diffusion metrics of the “normal appearing” WM tracts
can be separately analyzed from the diffusion within the
various types of white matter lesions including WMH,
lacunar infarcts, and cortical-subcortical stroke lesions.
Details of ONDRI DTI analysis pipeline are discussed
elsewhere (1).

Frontiers in Neurology | www.frontiersin.org

The SABRE-LE method segments sCSF and vCSF into
separate compartments. The initial T1-based segmentation
automatically labels hypointense voxels into a CSF class, and
then the ventricles are manually relabelled to a vCSF class
by neuroimaging analysts following a standardized procedure.
Note that although some vCSF segmentation tools based on
standardized templates use smoothing algorithms that reclassify
all voxels within the ventricular compartment as ventricles,
the SABRE-LE method does not. With the SABRE-LE method,
choroid plexus are not arbitrarily removed or re-classified as
CSF and thus remain as part of the overall tissue segmentation.
Ventricular volumes are often used as a simple indicator
of overall brain atrophy, and have the potential for use
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as a differential indicator of disease and dementia severity
(Figure 6) (43–45).

changes on nEuroimaging (STRIVE) (46) have established a set
of criteria that recommends the use of the term white matter
hyperintensities of presumed vascular origin (WMH), as the
standard terminology to refer to these regions of hyperintense
(bright) signal found on particular MRI. It is important to note
that as previously mentioned, WMH do not appear hyperintense
on all types of MRIs and often appear isointense to GM on
T1 (Figure 7). Additionally, despite the naming convention,
it is important to note that WMH are not limited to the
white matter regions of the brain, as they are also commonly
observed in subcortical GM structures such as the basal ganglia
and thalamus. However, to avoid confusion between studies,
ONDRI recommends the use of the more popular term “white
matter hyperintensities.”

White Matter Hyperintensities of Presumed
Vascular Origin (WMH)
Also referred to as leukoaraiosis, white matter lesions, subcortical
hyperintensities, and even, unidentified bright objects, WMH are
radiological anomalies commonly associated with cerebral small
vessel disease. Recently, the STandards for ReportIng Vascular

Periventricular (pWMH) and Deep White (dWMH)
Hyperintensities
Although WMH can be subdivided using SABRE ROIs, the
most common regional delineation of WMH is the separation
between periventricular (pWMH) and deep white (dWMH).
Historically controversial (47, 48), this concept is based on
several theories and research findings which suggest that WMH
in close proximity to the ventricles (hence the term “periventricular”) have a different pathological etiology (49, 50) and
are differentially correlated with cognitive/behavior deficits in
comparison to the more distal dWMH (despite the confusing fact
that pWMH are technically found in deeper white matter than
dWMH). Additionally, recent imaging-pathology correlations
suggest that a common substrate of pWMH relates to vasogenic
edema due to leakage and increased vascular resistance caused
by venous collagenosis, a small vessel venular disease of the deep
medullary venules (as opposed to the arterial side of the cerebral
vasculature) (51–53). It is also interesting to note that there is no
standard consensus in the literature on how to define pWMH vs.
dWMH, with some papers using a proportional distance to the
dura mater (54), some using an arbitrary cut-off (typically 13 mm
from the ventricles) (55), and others using a 3D connectivity

FIGURE 6 | Top row shows axial view of vCSF segmentation overlayed on T1
MRI for patients with AD (left) and FTD (right). Bottom row shows 3D surface
volume renderings of the vCSF segmentation. Note the differences in ventricle
size and the hemispheric differences between the two neurodegenerative
diseases.

FIGURE 7 | Axial view of various coregistered structural MRI sequences showing the relative intensity differences of WMH. Note that white matter hyperintensities are
not hyperintense (i.e., bright) on T1-weighted MRI.

Frontiers in Neurology | www.frontiersin.org
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FIGURE 8 | Shows different methods for segmenting periventricular and deep WMH. Left image shows a proportional distance from the ventricular lining to the dura
mater; middle image shows an arbitrary distance of 13 mm from ventricles, right image shows 3D connectivity algorithm supported by ONDRI, displayed as 3D
volume renderings of pWMH (red) and dWMH (blue) shown in sagittal and slightly tilted anterior views.

FLAIR, particularly in the basal ganglia region. Current research
suggests that PVS found in the white matter regions may indicate
Cerebral Amyloid Angiopathy (CAA), while PVS in the basal
ganglia may be more indicative of hypertensive arteriopathy (68–
71). Moreover, recent basic science research and limited clinical
evidence supports the theory that clearance of amyloid and other
metabolites occurs primarily during deep sleep (72, 73).
Previously referred to as dilated Virchow-Robin spaces,
measurement of PVS burden is typically accomplished using
visual rating scales under this old naming convention (74,
75). However, the novel quantitative method supported by
ONDRI provides a volumetric measure of PVS. This method
has been previously validated with common PVS visual scales
and has been used to study AD, normal elderly, and stroke
and cerebrovascular disease patients being assessed with sleep
polysomnography (72, 76). Although both lacunes and PVS
volumes are segmented automatically using the SABRE-LE
pipeline, false positive minimization procedures are manually
performed to remove incorrect segmentations and to reallocate
PVS to lacunes or vice versa depending on strict intensity
and shape-based criteria. Only highly trained neuroimaging
analysts achieving ICCs and DICE Similarity Indices (SI) > 0.90
are allowed to perform this procedure. Moreover, a research
neuroradiologist (FG) was consulted when faced with complex
radiological anomalies that were commonly observed in the CVD
patient cohort.

algorithm (23, 56)—the method that is currently supported by
ONDRI (see Figure 8).

Lacunes
Lacunes of presumed vascular origin are cystic fluid-filled cavities
in the subcortical brain regions (57, 58). They appear hypointense
(dark) on T1, hyperintense (bright) on PD and T2, and can
appear as a lesion with a hypointense central core surrounded by
a hyperintense rim/halo on FLAIR MRI (Figure 9, bottom row).
The recent STRIVE criteria (46) provides some consensus-based
guidelines regarding their definition, however, previous studies
have used various terms (e.g., “white matter lesions,” “lacunar
infarcts,” “covert strokes”) and radiological descriptions to classify
these lesions (59). Often difficult to differentiate from MRIvisible perivascular spaces (PVS) (next section), lacunes tend to
be larger and less linear than PVS. They are associated with
increased risk of stroke, dementia, and gait disturbances (60). It
is important to note that due to the poor sensitivity of FLAIR in
thalamic regions (61) (Figure 9, top row), the ONDRI imaging
pipeline integrates an additional T2-based segmentation in order
to capture any potential lesions in this subcortical region that may
not appear on FLAIR.

MRI-Visible (Enlarged) Perivascular Spaces
(PVS)
Recent studies suggest that the brain utilizes the glymphatic
system (62, 63) to clear fluid and metabolic waste, using
a complex series of perivascular channels surrounding the
brain’s veins and arteries. It has been suggested that when
the perivascular channels are compromised due to aging,
disease, or trauma, the perivascular space becomes enlarged
and consequently, visible on structural MRI (64–67). MRIvisible (enlarged) perivascular spaces (PVS) on T2 appear as
small (<3 mm diameter), linear, hyperintensities following the
course of the vasculature (Figure 10). Additionally, PVS appear
hypointense (dark) on T1, isointense to GM on PD (vs. lacunes
which are bright on PD), and are very difficult to visualize on 2D
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Cerebral Microbleeds
Although the SABRE-LE structural pipeline method used
by ONDRI does not support a cerebral microbleed (CMB)
segmentation algorithm, this brief section has been included to
describe this important measure of cerebral small vessel disease
burden. In ONDRI, CMB, and superficial siderosis burden are
being assessed visually by a highly qualified neuroradiologist
(SS). Cerebral microbleeds (CMB) have been shown to reflect
perivascular leakage of red blood cells that can be visualized as
low signal intensities (hypointense/dark spots) on T2∗ -weighted
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FIGURE 9 | Top row shows a thalamic lacune as it appears on different coregistered MRI, hypointense (dark) on T1, hyperintense on PD-T2, and difficult to detect on
FLAIR. In contrast, the bottom row shows a subcortical lacunar infarct that presents with the classic central CSF-like hypointensity with a surrounding hyperintense
halo/rim on FLAIR.

gradient-recalled echo (GRE) (Figure 11) and susceptibility
weighted imaging (SWI) (77). There are two commonly used
methods of assessing CMB burden, the Microbleed Anatomical
Rating Scale (MARS) (78) and the Brain Observer MicroBleed
Scale (BOMBS) (79) visual rating scales. Previous studies
have shown that CMB are associated with an increased risk
of stroke, intracerebral hemorrhage, cognitive decline, and
dementia (80–84). Differences in anatomical distribution suggest
that CMB found in deep centrencephalic brain regions (basal
ganglia, thalamus, and brain stem) are more closely related
to hypertensive arteriopathy (85), while lobar CMB are more
closely associated with CAA and AD pathology (86–89), leading
to the development of the Boston criteria for the diagnosis of
possible/probable CAA (90, 91).

technologies (95); managing transitions of care following stroke
(96); mood, cognition, and fatigue following stroke (97);
hyperacute stroke care (98); secondary prevention of stroke (99);
and stroke during pregnancy (100, 101).
Although the term “stroke” may encompass a wide range of
clinical criteria (102), the Vascular Cognitive Impairment (VCI)
(18) inclusion-exclusion criteria for ONDRI CVD patients was
limited to mild-moderate ischemic stroke patients, defined by a
Modified Rankin Scale (MRS) (103) score of 0–3. It is important
to note that although there are a number of imaging techniques
used to measure acute stroke in the early stages (within a couple
of hours of stroke), the MRI methods applied to ONDRI CVD
patients are measures of post-stroke lesions, often referred to as
chronic stroke, with structural MRI acquired > 3 months post
ischemic stroke event.
As there are currently no reliable automatic ways to
quantify the range of cortico-subcortical stroke lesions, ONDRI
neuroimaging analysts manually delineate the stroke under
the direct supervision of a highly experienced research
neuroradiologist (FG). This manual delineation is strictly limited
to cortical strokes appearing as hyperintense (bright) on FLAIR
and hypointense (dark) on T1, although the entire stroke
volume often extended into the subcortical regions of the brain
(Figure 12). Although this total volume does not separate the
hypointense necrotic stroke core from the surrounding partially

Chronic Stroke
According to recent estimates, stroke is the 2nd most common
cause of death worldwide (92) and the second leading cause
of dementia (93). In a 2013 global report, there were ∼25.7
million stroke survivors, and 7.5 million deaths from ischemic
and hemorrhagic stroke (94). In Canada, ∼62,000 people are
treated for stroke and transient ischemic attack. In a series of
publications, the Heart and Stroke Foundation Canadian Best
Practice Committees have been developing various evidencebased recommendations to address issues regarding: telestroke
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FIGURE 11 | Axial view of iron-sensitive T2* gradient echo (GRE) with red
arrow pointing to cerebral microbleeds visualized as hypointensities (dark).

and between-study comparisons; however, statistical analyses
should generally be performed on head-size corrected volumes.
Head size correction accounts for individual variations in
intracranial capacity and sex-related differences in head size
(104). Additionally, depending on the research question, the
volume of interest (i.e., NAWM, NAGM, CSF, or WMH)
could also be reported as a proportion of the total volume
within each SABRE region, or they can be reported as a
proportion of the total head-size (ST-TIV) for age-independent
normalization/correction. The version or date of the data release
should also be reported.
There are several ways that WMH can be analyzed and it
depends on the research question in mind. The simplest approach
is to sum the dWMH and pWMH, which results in a whole
brain measure of small vessel disease burden. Regional analyses
of WMH can also be performed to assess WMH burden within
a SABRE ROI. Additionally, WMH within different ROIs can
be combined by simply summing the volumes from different
SABRE regions to generate a larger ROI (e.g., sum all pWMH
and dWMH volumes within all frontal SABRE brain region
parcellations using the Frontal Lobe Codes shown on Table 1).
It is important to note that many measures of cerebral
small vessel disease, such as pWMH and dWMH, are typically
non-normally distributed (105), often inter-correlated (54), are
known to be age-related (106), and commonly associated with
vascular risk factors such as hypertension (107). Thus, careful
attention to these factors and previous research findings highlight
ONDRI’s recommendation to consider these additional factors
when analyzing imaging-based markers of cerebral small vessel

FIGURE 10 | Examples of the PVS segmentation (red and yellow) over-layed
onto structural MRI in axial (top 2 rows) and coronal views (bottom row).

infarcted hyperintense region indicating varying degrees of
gliosis and encephalomalacia, future automatic segmentation
techniques are currently being tested in ONDRI to include
this sub-segmentation.

RECOMMENDATIONS FOR REPORTING
AND ANALYSIS
Here we provide some general guidelines for reporting and
analysis that can be useful for researchers wishing to use
ONDRI data.
First and foremost, when reporting data for characterization
of the sample being analyzed, we recommend that the
original raw volumes are reported in tables for transparency

Frontiers in Neurology | www.frontiersin.org
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FIGURE 12 | Axial view of coregistered structural MRI sequences (left to right): T1, PD, T2, and FLAIR. Images illustrate relative intensity differences of a large
cortico-subcortical stroke lesion across various types of MRI. The last pane shows ONDRI’s manual segmentation of the entire stroke core and surrounding
hyperintense partially infarcted tissue volume in green.

FIGURE 13 | Descriptive violin plots of the ONDRI disease cohorts showing median and interquartile range volumetrics for whole brain supratentorial total intracranial
volume (ST-TIV), normal appearing gray matter (NAGM), normal appearing white matter (NAWM), sulcal cerebrospinal fluid (sCSF), ventricular CSF (vCSF), MRI-visible
enlarged perivascular space (PVS) volumes, periventricular white matter hyperintensities (pWMH), deep WMH (dWMH), and lacunes (LACN).

disease. Given the skewed, non-normal distribution of WMH
(even after head-size correction), WMH volumes are typically
transformed (e.g., log) prior to standard parametric analyses.
For this reason, approaches designed to deal with complex
distributions should be considered (108).

Frontiers in Neurology | www.frontiersin.org

Since the pipeline automatically segments lesions in the
periventricular region from the deep white regions, the lacunar
volumes are also provided in this manner. While some future
studies may argue a pathophysiological difference between these
two locations of lacunar presentation, there are currently limited
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significant challenges to common imaging analysis tools. In
this paper, we presented the neuroimaging pipeline methods
implemented in ONDRI that were used to overcome many of
these challenges.
To further ensure a high level of data quality, the volumetric
data generated by the ONDRI structural neuroimaging team
were further subjected to comprehensive quality control analysis
pipelines including a novel multivariate outlier detection
algorithm developed by the ONDRI neuroinformatics group for
identification of anomalous observations (114, 115). Future work
will include generating longitudinal measures that will also be
made publicly available. As the neuroimaging data are combined
with releases from ONDRI’s clinical, neuropsychology, genomics,
eye tracking, gait and balance, ocular, and neuropathology
platforms, it becomes evident that ONDRI is a gold mine of
data opening the door to an unprecedented broad range of
cross-platform analyses resulting in numerous opportunities for
discovery and advances in diagnosis, prognosis, outcomes, and
care of neurodegenerative diseases.

studies to suggest this anatomical delineation. Given this, we
recommend that the two volumes be summed together prior to
analysis. Interestingly, lacunes and PVS volumes are not typically
head-size corrected in the clinical/scientific literature, however,
age, sex, WMH, and a measure of brain atrophy (e.g., BPF or
vCSF), and proper accounting of vascular risk are recommended
covariates when analyzing lacunes and PVS (109, 110). Note that
in many publications, lacunes, and PVS are reported as counts
(i.e., number of), because they are often measured using visual
rating methods that require the user to count the number of
lacunes or PVS observed on an MRI—often leading to wide
variations in definitions and conflicting findings in the literature
(59, 111). Since the lacunes and PVS in ONDRI are quantified
using segmentation based imaging analyses, PVS and lacunar
volumes are provided rather than counts.
Finally, any analyses using ONDRI’s CVD cohort should
consider the common comorbidities of depression, obstructive
sleep apnea, and cognitive impairment (112), as well the
subcortical silent brain infarcts/lacunes, WMH, and potentially,
CMB, which have recently been acknowledged as playing an
important role in primary stroke prevention (113).

DATA AVAILABILITY STATEMENT
The datasets generated for this study are available on request to
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RESULTS AND CONCLUSION
Of the n = 520 patients with MRI acquired, the ONDRI
neuroimaging pipeline was unable to process n = 1 FTD patient
due to extreme motion artifact (despite 2 baseline attempts
on 2 separate occasions), and n = 6 CVD patients due to
poor imaging quality (n = 3 FLAIR not usable, n = 2 T1
not usable, n = 1 PD/T2 not acquired). To illustrate whole
brain data extraction volumetric results from this pipeline,
neuroimaging summary statistics for each ONDRI disease cohort
are summarized on Table 2, and descriptive violin plots showing
median and interquartile ranges are provided for whole brain STTIV, NAGM, NAWM, sCSF, vCSF, pWMH, and dWMH PVS,
and LACN are displayed on Figure 13. Stroke volumes were not
graphed due to the limited number of ONDRI patients with
cortico-subcortical stroke lesions.
It is important to note that the details in this manuscript focus
on ONDRI’s baseline data that will be released in October 2020,
the longitudinal follow-up data will be forthcoming.
Additionally, a cohort of cognitively normal older adults
recruited from the Brain-Eye Amyloid Memory (BEAM)
study (clinicaltrials.gov—NCT02524405) with harmonized
neuroimaging, neuropsychology, and data acquisition protocol,
will be included in ONDRI for comparative analyses. Participants
in BEAM were recruited from five sites (Sunnybrook, Baycrest,
CAMH, SMH, and UHN) that also participated in ONDRI.
ONDRI is the first multi-site, multiple assessment platform
study examining several neurodegenerative and neurovascular
diseases using a harmonized protocol that includes standardized
structural neuroimaging. The wide range of complex, and often
overlapping, brain pathologies represented in this cohort of
neurodegenerative patients included a number of comorbid
cerebral small vessel disease markers, cortico-subcortical stroke
lesions, combined with focal and global atrophy, posing
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